Floatz logo

GD2-SADA

Malignant Melanoma

Y-mAbs TherapeuticsPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

449 Active assets in the Malignant Melanoma cohort.

Asset / SponsorPhaseRating
Gm-Csf
Ultimovacs ASA
Phase 4BBB
Sargramostim
Mayo Clinic
Phase 3BBB
Cediranib
M.D. Anderson Cancer Center
Phase 3BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Tebentafusp
Immunocore Ltd
Phase 3BB

View all 50 →

Same molecule, other indications

GD2-SADA is also rated in:

neuroblastomaDormant
CC
Indicative ·
43 / 100
View asset →
small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
sarcomaDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →